The goals are to understand why some people develop Alzheimer’s disease so early; look for genetic determinants of the disease and its early biomarkers; and track the progression of the disease. Ultimately, LEADS aims to provide insights that can contribute to therapies that may slow or stop progression of the disease and establish a network of clinical trial sites focused on this patient population.

While LEADS is focused on early-onset Alzheimer’s disease, it is expected that what is learned will also contribute to our understanding of late-onset disease.